Continuing with new TKI developments, DST was approved in 2006 for the treatment of adults in all stages of CML who are resistant or intolerant to IMT; DST is a potent inhibitor that acts on the SRC/ABL1 kinases [29]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.